28 patents
Utility
Ocular Implant Containing an Active Ingredient
7 Dec 23
The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
Charles D. BLIZZARD, Arthur DRISCOLL, Rami EL-HAYEK, Michael GOLDSTEIN, Joseph IACONA, Peter JARRETT, Timothy S. JARRETT, Erica KAHN, Zachary LATTRELL
Filed: 26 Oct 21
Utility
Sustained Release Biodegradable Intracanalicular Inserts Comprising a Hydrogel and an Active Agent
26 Oct 23
Provided herein are sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Charles D. BLIZZARD, Rami EL-HAYEK, Michael GOLDSTEIN, Peter JARRETT, Andrew VANSLETTE
Filed: 23 Sep 21
Utility
Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
10 Oct 23
Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Charles D. Blizzard, Rami El-Hayek, Michael Goldstein, Peter Jarrett, Andrew Vanslette
Filed: 25 Feb 22
Utility
Ocular Implant Containing an Active Ingredient
14 Sep 23
The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
Charles D. BLIZZARD, Arthur DRISCOLL, Rami EL-HAYEK, Michael GOLDSTEIN, Joseph IACONA, Peter JARRETT, Timothy S. JARRETT, Erica KAHN, Zachary LATTRELL
Filed: 14 Mar 23
Utility
Compositions and Methods for Treating Ocular Diseases
14 Sep 23
The present invention relates to the treatment of ocular diseases in a human subject.
Charles D. Blizzard, Ankita Desai, Arthur Driscoll, Michael Goldstein
Filed: 14 Dec 22
Utility
Ocular Implant Containing a Tyrosine Kinase Inhibitor
20 Apr 23
The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
Filed: 21 Nov 22
Utility
Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles
11 Apr 23
The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
Charles D. Blizzard, Ankita Desai, Arthur Driscoll, Michael Goldstein
Filed: 16 Feb 22
Utility
Ocular Hydrogel Tyrosine Kinase Inhibitor Implants
9 Feb 23
Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.
Peter Jarrett, Rami El-Hayek, Timothy S. Jarrett, Zachary Lattrell, Arthur Driscoll, Charles D. Blizzard
Filed: 3 Aug 22
Utility
Punctal plug and bioadhesives
24 Jan 23
The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye.
Noah Silverberg, Mark Silverberg
Filed: 24 Sep 22
Utility
Punctal Plug and Bioadhesives
19 Jan 23
The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye.
Noah Silverberg, Mark Silverberg
Filed: 24 Sep 22
Utility
Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor
27 Dec 22
This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.
Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
Filed: 13 May 22
Utility
Ocular Implant Containing a Tyrosine Kinase Inhibitor
3 Nov 22
The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
Filed: 13 May 22
Utility
Punctal plug and bioadhesives
4 Oct 22
The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye.
Noah Silverberg, Mark Silverberg
Filed: 7 Oct 16
Utility
Ocular implant containing a tyrosine kinase inhibitor
13 Sep 22
The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
Filed: 24 Mar 21
Utility
Methods of Treating Allergic Conjunctivitis
14 Jul 22
Disclosed is a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel.
Michael Goldstein
Filed: 16 Feb 22
Utility
Compositions and Methods for Treating Ocular Diseases
14 Jul 22
The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
Charles D. Blizzard, Ankita Desai, Arthur Driscoll, Michael Goldstein
Filed: 16 Feb 22
Utility
Sustained Release Biodegradable Intracanalicular Inserts Comprising a Hydrogel and Cyclosporine
30 Jun 22
Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Charles D. Blizzard, Rami El-Hayek, Michael Goldstein, Peter Jarrett, Andrew Vanslette
Filed: 25 Feb 22
Utility
Ocular Insert Containing a Glucocorticoid
16 Jun 22
In certain embodiments, the invention relates to a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel for the treatment of dry eye disease.
Charles D. Blizzard, Ankita Desai, Michael Goldstein
Filed: 13 Dec 21
Utility
Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
17 May 22
Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Charles D. Blizzard, Rami El-Hayek, Michael Goldstein, Peter Jarrett, Andrew Vanslette
Filed: 23 Sep 21
Utility
Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
5 Apr 22
Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Charles D. Blizzard, Rami El-Hayek, Michael Goldstein, Peter Jarrett, Andrew Vanslette
Filed: 23 Sep 21